Tempus Partners With Cleveland Clinic on Precision Cancer Rx Study

NEW YORK (GenomeWeb) – Tempus announced today that it has partnered with the Cleveland Clinic on a study identifying personalized therapies for cancer patients.

Under the terms of the deal, Tempus will provide molecular sequencing and data analysis for patients with metastatic or incurable cancer who are enrolled in a precision medicine study at the Cleveland Clinic’s Taussig Cancer Institute. The trial aims to identify patients who may be candidates for specific targeted therapies and/or clinical trials, as well as to uncover clinically significant genetic patterns.

“Incorporating advanced genomic data may enhance our ability to analyze vast amounts of clinical and molecular data as we seek to improve the treatment options for our patients,” Taussig Chairman Brian Bolwell said in a statement.

In August, Tempus began working with the University of California Davis Comprehensive Cancer Center to develop personalized medicine regimens for cancer patients, and in June it formed a collaboration with University of Chicago Medicine to study clinical and molecular data from pancreatic cancer patients in order to improve the prediction of treatment responses. It also recently struck a similar arrangement with the University of Michigan focused on breast cancer.

Be the first to comment

Leave a Reply

Your email address will not be published.